Phase Ib dose-escalation/expansion study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumours... von Girard, N., Hackanson, B., Wermke, M., Barlesi, F., Landsteiner, H.T., Jayadeva, G., Alt, J.

Volltext

1593TiP - Phase Ib dose-escalation/expansion study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced sol... von Girard, N., Hackanson, B., Wermke, M., Barlesi, F., Landsteiner, H.T., Jayadeva, G., Alt, J.

Volltext

533MO Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with solid tumours von Girard, N., Wermke, M., Barlesi, F., Kim, D-W., Ghiringhelli, F., Landsteiner, H.T., Jayadeva, G., Alt, J., Hackanson, B.

Volltext

532P Phase Ib study evaluating BI 836880 (VEGF/Ang2 nanobody) in combination with ezabenlimab (BI 754091; anti-PD-1 antibody) in patients with solid tumours von Girard, N., Wermke, M., Ledin, E., Kim, D-W., Ghiringhelli, F., Bennouna, J., Lesimple, T., Felip, E., Berz, D., Lee, J-S., Jeanson, A., Mascaux, C., Voskoboynik, M., Serwatowski, P., Burger, M.C., Landsteiner, H.T., Chen, V., Jayadeva, G., Alt, J., Hackanson, B.

Volltext

56O A phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin (BI 907828): Safety and efficacy in patients with dedifferentiated liposarcoma von Schöffski, P., Lorusso, P., Yamamoto, N., Reichardt, P., Schwartz, L., Dercle, L., Zhao, B., Chitalia, R., Montgomery, G., Hu, C., Landsteiner, H.T., Jayadeva, G., Gounder, M.

Volltext

61MO Phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin (BI 907828) in advanced solid tumours: Overall safety, and efficacy in patients (pts) with well-differentiated liposar... von Reichardt, P., Schöffski, P., Lorusso, P., Yamamoto, N., Garcia, V. Moreno, Lugowska, I., Lauer, U., Somaiah, N., Hu, C., Landsteiner, H.T., Jayadeva, G., Gounder, M.

Volltext